Evidence map›Paper›PMID 11320237›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2001

Mapping of contact sites in complex formation between transducin and light-activated rhodopsin by covalent crosslinking: use of a photoactivatable reagent.

K Cai, Y Itoh, H G Khorana

Open access · greenAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.

0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed
4.1field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

47 citing papers in PubMed, 140 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors at 1 institution in 2 countries.

K CaiDepartments of Biology and Chemistry, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
Y Itoh
H G Khorana
Massachusetts Institute of Technology · US

Funding

SYNTHETIC AND BIOLOGICAL STUDIES OF NUCLEIC ACIDSR01GM028289 · NIGMS · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI KHORANA, H. GOBIND · 1985 to 2003
$2.9M
CARCINOGENESIS AND DRUG DEVELOPMENTT32CA009112 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI LIPPARD, STEPHEN J · 1985 to 2005
$2.2M
Role of ubiqutin in quality control of lens proteinsR01EY011717 · NEI · TUFTS UNIVERSITY BOSTON · PI SHANG, FU · 2003 to 2010
$1.8M
UBIQUITIN DEPENDENT PATHWAY AND LENS EPITHELIUMR29EY011717 · NEI · TUFTS UNIVERSITY BOSTON · PI SHANG, FU · 1998 to 2002
$381k
SYNTHETIC &BIOLOGICAL STUDIES OF NUCLEIC ACIDSR37GM028289 · NIGMS · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI KHORANA, H. GOBIND · 1986 to 1995
–
NCI NIH HHS CA 09112NCI NIH HHS T32 CA009112NEI NIH HHS EY11717NEI NIH HHS R01 EY011717NEI NIH HHS R29 EY011717NIGMS NIH HHS GM28289NIGMS NIH HHS R01 GM028289
6 · The paper itself

Abstract

Interaction of light-activated rhodopsin with transducin (T) is the first event in visual signal transduction. We use covalent crosslinking approaches to map the contact sites in interaction between the two proteins. Here we use a photoactivatable reagent, N-[(2-pyridyldithio)-ethyl], 4-azido salicylamide. The reagent is attached to the SH group of cytoplasmic monocysteine rhodopsin mutants by a disulfide-exchange reaction with the pyridylthio group, and the derivatized rhodopsin then is complexed with T by illumination at lambda >495 nm. Subsequent irradiation of the complex at lambda310 nm generates covalent crosslinks between the two proteins. Crosslinking was demonstrated between T and a number of single cysteine rhodopsin mutants. However, sites of crosslinks were investigated in detail only between T and the rhodopsin mutant S240C (cytoplasmic loop V-VI). Crosslinking occurred predominantly with T(alpha). For identification of the sites of crosslinks in T(alpha), the strategy used involved: (i) derivatization of all of the free cysteines in the crosslinked proteins with N-ethylmaleimide; (ii) reduction of the disulfide bond linking the two proteins and isolation of all of the T(alpha) species carrying the crosslinked moiety with a free SH group; (iii) adduct formation of the latter with the N-maleimide moiety of the reagent, maleimido-butyryl-biocytin, containing a biotinyl group; (iv) trypsin degradation of the resulting T(alpha) derivatives and isolation of T(alpha) peptides carrying maleimido-butyryl-biocytin by avidin-agarose chromatography; and (v) identification of the isolated peptides by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. We found that crosslinking occurred mainly to two C-terminal peptides in T(alpha) containing the amino acid sequences 310-313 and 342-345.

Indexed as

Amino Acid SequenceAnimalsAzidesBinding SitesCattleCOS CellsCross-Linking ReagentsCysteineDisulfidesDithiothreitolEthylmaleimideGuanosine DiphosphateLightLysineMaleimidesModels, MolecularAzidesCross-Linking ReagentsCysteineDisulfidesDithiothreitolEthylmaleimideGuanosine DiphosphateLysineMaleimidesmaleimido-butyryl-biocytinN-((2-pyridyldithio)ethyl)-4-azidosalicylamidePyridinesRhodopsinSepharoseTransducinTrypsin

Identifiers

PMID11320237
PMCPMC33131
OpenAlexW2016441306

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.